Immunosuppressive Therapy in Heart Transplantation

Immunosuppressive Therapy in Heart Transplantation

Yan Li (Cleveland Clinic, USA), April Yingfang Li (Northeast Ohio Medical University, USA), Ifeyinwa S. Nwankwo (Case Western Reserve University School of Medicine, USA), Zhi Huang (Cleveland Clinic, USA), Bin Zhang (Mayo Clinic, USA), Yun Lu (No. 1 Hospital of Lanzhou University, China) and Yali Yao (No. 1 Hospital of Lanzhou University, China)
Copyright: © 2017 |Pages: 20
DOI: 10.4018/978-1-5225-2092-4.ch012

Abstract

Heart transplantation is a surgical procedure performed on patients with end-stage heart failure or other irreversible heart disease, Heart transplant prolongs the life of severe heart disease patients. Most of the receipts could survive more than 2-3 years, five-year survival rate could reach 70-80% with immunosuppressive therapy, rejection still an important problem after transplantation. Currently, traditional calcineurin inhibitors, antimetabolite agents, and steroids, wildly used after transplantation, the new generation of immunosuppressive medicines have been developed, and cell-based immunotherapy, as mesenchymal stem cell, myeloid-derived suppressor cells, dendritic cells, pluripotent cells and Treg cells are promising to be used in cellular immunotherapy in organ transplantation.
Chapter Preview
Top

Introduction

The chapter focused on heart transplantation indication, prognosis, traditional and new generation immunosuppressive medicine, cell immunotherapy in adult and pediatric heart transplantation.

Complete Chapter List

Search this Book:
Reset